Nav: Home

High-risk pulmonary embolism patients often go without most effective treatments

March 18, 2017

PHILADELPHIA -- Pulmonary embolism (PE), a blood clot in the lungs which causes shortness of breath and chest pain, is the third leading cardiovascular cause of death in the United States with more than 100, 000 lives taken each year. A typical intervention for PE patients includes anticoagulants in an effort to prevent migration of the blood clot, but the higher-risk PE population -- about 30 percent of all PE patients -- are potential candidates for catheter-directed thrombolysis (CDT) and systemic thrombolysis (ST), both of which employ "clot-busting" medications known as tissue plasminogen activator (tPA).

However, in a new study presented today at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilization rates of these potentially life-saving medications are low, particularly in the sub-group of PE patients who are critically ill.

ST is the method in which "clot-busting" medication is administered intravenously (IV) to eliminate clots throughout the bloodstream, while CDT allows the medication to be directly administered into the clot in the lungs.

"For years, ST and CDT have been available for use in patients with PE, however, there has been little research done to understand how these therapies are being utilized in the real-world," said the study's presenter Srinath Adusumalli, MD, chief cardiovascular medicine fellow in the Perelman School of Medicine at the University of Pennsylvania. "Our initial data suggest that, in fact, both ST and CDT are used infrequently to treat PE, including in young, critically ill patients who may experience the highest clinical benefit from those therapies."

Adusumalli and his colleagues performed a retrospective study in which they collected data from the OptumInsight national commercial insurance claims database and identified 100,744 patients who had been hospitalized with PE during a ten-year period (2004-2014). This is the first study of its kind to examine detailed procedural coding for pulmonary embolism therapies from a national database, allowing researchers to aggregate information from a national population rather than hospital or region-specific information. The team culled through the data and found that of the 100,744 patients hospitalized with PE, 2,175 patients received either CDT or ST - roughly two percent of all PE patients. In this same timeframe, the number of PE hospitalizations increased by 306 percent.

"Another question that emerged from these findings is whether we are adequately matching the right patients to the right therapies at the right time," said senior author Peter W. Groeneveld, MD, MS, an associate professor of Medicine, research director in the Leonard Davis Institute of Health Economics, and director of Penn's Cardiovascular Outcomes, Quality, and Evaluative Research Center. "Since there is a lack of real-world clinical effectiveness and safety data on these therapies and a resulting lack of guideline-based recommendations, substantial clinical uncertainty persists as to when and in whom to use CDT and ST."

A larger team at Penn Medicine, including those who were involved with this study, created what's called the Pulmonary Embolism Response Team -- or PERT -- which is designed to employ rapid response techniques for the treatment of PE in order to match the right patient to the right therapy at the right time.

"The purpose of PERT is to ensure that high-risk PE patients are receiving the best kind of treatment plan on the most efficient timeline in order to improve outcomes," said Jay Giri, MD, MPH, an assistant professor of Cardiovascular Medicine and founder of the PERT at the Hospital of the University of Pennsylvania. "However, it is important to state that most decisions made by PERT physicians are a matter of clinical consensus rather than being based on rigorous comparative effectiveness research. The current study re-emphasizes the clinical consequences of the dearth of data in the PE field."

While the team notes these data are clinically useful and could impact the patient care decision-making process, there is still more research needed. Co-presenter and study author Bram Geller, MD, a cardiovascular medicine fellow in the Perelman School of Medicine at the University of Pennsylvania, added, "this study is the first in a two-step research plan, in which our next phase will be to actually evaluate the safety and clinical effectiveness of CDT versus ST by exploring patient outcomes in the OptumInsight commercial insurance claims database."
-end-
Additional Penn authors on this study include Lin Yang. This study is one of the first to be supported by Penn's Cardiovascular Outcomes, Quality, and Evaluative Research Center (CAVOQER) within the Leonard Davis Institute of Health Economics. Adusumalli is supported by a National Institutes of Health T32 training grant (3T32HL007843-20S1).

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.

University of Pennsylvania School of Medicine

Related Pulmonary Embolism Articles:

Short or long sleep associated with Pulmonary Fibrosis
Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.
Better way to interpret blood tests to diagnose pulmonary embolism
A study led by Hamilton researchers has found a new way to interpret blood test results in patients who are investigated for blood clots in their lungs, a condition known as pulmonary embolism.
Reversed halo signs manifest in septic pulmonary embolism due to IV drug use
According to an article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology (AJR), reversed halo signs were frequently observed on the chest CT scans of patients with IV substance use disorder-related septic pulmonary embolism.
Treating pulmonary embolism: How safe and effective are new devices?
A new scientific statement from the American Heart Association identifies the risks and benefits of novel interventional devices compared to anticoagulation alone in the treatment of patients with pulmonary embolism.
Promising steps towards a treatment for pulmonary fibrosis
Research published in the journal Science Translational Medicine on 25 September by members of the Cardiovascular Disease Mechanisms group at the MRC LMS in collaboration with Duke-NUS Medical School, National Heart Centre Singapore & National Heart and Lung Institute, Imperial College London, showed that blocking a protein called interleukin-11 (IL-11) using therapeutic antibodies can reverse the fibrosis in the lung.
African-Americans with COPD appear less likely to use pulmonary rehab
African-American patients with chronic obstructive pulmonary disease, or COPD, are less likely to participate in pulmonary rehabilitation programs than white patients, even when there are programs nearby.
Lung-on-a-chip simulates pulmonary fibrosis
New biotechnology reported in the journal Nature Communications could make testing potential medicine for pulmonary fibrosis, one of the most common and serious forms of lung disease, quicker and less expensive.
Study identifies new target for treatment of pulmonary hypertension
Inhibiting FoxM1 gene reverses disease process in animal models of pulmonary hypertension.
Pulmonary fibrosis caused by single transcription factor
Reduced FoxO3 activity reprograms connective tissue cells, triggering the disease.
Lung cancer triggers pulmonary hypertension
Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension.
More Pulmonary Embolism News and Pulmonary Embolism Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.